{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:14:35Z","timestamp":1788491675578,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s13300-024-01674-8","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T05:47:36Z","timestamp":1734760056000},"page":"269-287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Bioequivalence Study of Two Formulations of Oral Semaglutide in Healthy Participants"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct05227196","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7354-4648","authenticated-orcid":false,"given":"Mette S\u00f8ndergaard","family":"Nielsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Br\u00f8ndsted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4168-4838","authenticated-orcid":false,"given":"Martin","family":"Kankam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8238-8751","authenticated-orcid":false,"given":"Gaetano","family":"Morelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8562-1977","authenticated-orcid":false,"given":"David","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4101-4703","authenticated-orcid":false,"given":"Trine Vang","family":"Skj\u00f8th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4815-3300","authenticated-orcid":false,"given":"Usha Rani","family":"Patted","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5753-9563","authenticated-orcid":false,"given":"Marloes","family":"van Hout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"issue":"12","key":"1674_CR1","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925\u201366.","journal-title":"Diabetologia"},{"issue":"3","key":"1674_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.330","volume":"5","author":"M Bl\u00fcher","year":"2022","unstructured":"Bl\u00fcher M, Ceriello A, Davies M, et al. Managing weight and glycaemic targets in people with type 2 diabetes-How far have we come? Endocrinol Diabetes Metab. 2022;5(3): e00330.","journal-title":"Endocrinol Diabetes Metab"},{"issue":"Suppl 1","key":"1674_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/dom.13137","volume":"20","author":"S Tran","year":"2018","unstructured":"Tran S, Retnakaran R, Zinman B, Kramer CK. Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2018;20(Suppl 1):68\u201376.","journal-title":"Diabetes Obes Metab"},{"issue":"10157","key":"1674_CR4","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329.","journal-title":"Lancet"},{"key":"1674_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645617","volume":"12","author":"JJ Meier","year":"2021","unstructured":"Meier JJ. Efficacy of semaglutide in a subcutaneous and an oral formulation. Front Endocrinol (Lausanne). 2021;12: 645617.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1674_CR6","unstructured":"U.S. Food and Drug Administration. Ozempic\u00ae Prescribing Information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf. Accessed 20 June 2024."},{"key":"1674_CR7","unstructured":"European Medicines Agency. Ozempic\u00ae Summary of Product Characteristics. 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ozempic-epar-product-information_en.pdf. Accessed 20 June 2024."},{"issue":"6","key":"1674_CR8","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40262-018-0728-4","volume":"58","author":"C Granhall","year":"2019","unstructured":"Granhall C, Donsmark M, Blicher TM, et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clin Pharmacokinet. 2019;58(6):781\u201391.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"1674_CR9","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S2213-8587(19)30182-2","volume":"7","author":"MA Nauck","year":"2019","unstructured":"Nauck MA, Meier JJ. Pioneering oral peptide therapy for patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2019;7(7):500\u20132.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"1674_CR10","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2337\/dc19-0749","volume":"42","author":"VR Aroda","year":"2019","unstructured":"Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724\u201332.","journal-title":"Diabetes Care"},{"issue":"12","key":"1674_CR11","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2337\/dc19-0883","volume":"42","author":"HW Rodbard","year":"2019","unstructured":"Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: The PIONEER 2 trial. Diabetes Care. 2019;42(12):2272\u201381.","journal-title":"Diabetes Care"},{"issue":"15","key":"1674_CR12","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1001\/jama.2019.2942","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: The PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466\u201380.","journal-title":"JAMA"},{"issue":"10192","key":"1674_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","volume":"394","author":"R Pratley","year":"2019","unstructured":"Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019;394(10192):39\u201350.","journal-title":"Lancet"},{"issue":"7","key":"1674_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):515\u201327.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"1674_CR15","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.2337\/dc19-0898","volume":"42","author":"B Zinman","year":"2019","unstructured":"Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: The PIONEER 8 trial. Diabetes Care. 2019;42(12):2262\u201371.","journal-title":"Diabetes Care"},{"issue":"9","key":"1674_CR16","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841\u201351.","journal-title":"N Engl J Med"},{"issue":"5","key":"1674_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S2213-8587(20)30075-9","volume":"8","author":"Y Yamada","year":"2020","unstructured":"Yamada Y, Katagiri H, Hamamoto Y, et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2\/3a, randomised, controlled trial. Lancet Diabetes Endocrinol. 2020;8(5):377\u201391.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"1674_CR18","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S2213-8587(19)30194-9","volume":"7","author":"TR Pieber","year":"2019","unstructured":"Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2019;7(7):528\u201339.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1674_CR19","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","volume":"8","author":"D Yabe","year":"2020","unstructured":"Yabe D, Nakamura J, Kaneto H, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2020;8(5):392\u2013406.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1674_CR20","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s00125-024-06142-3","volume":"67","author":"W Wang","year":"2024","unstructured":"Wang W, Bain SC, Bian F, et al. Efficacy and safety of oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes (PIONEER 11): a double-blind, Phase IIIa, randomised trial. Diabetologia. 2024;67:1783\u201399.","journal-title":"Diabetologia"},{"key":"1674_CR21","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1007\/s00125-024-06133-4","volume":"67","author":"L Ji","year":"2024","unstructured":"Ji L, Agesen RM, Bain SC, et al. Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin: PIONEER 12, a double-blind, Phase IIIa, randomised trial. Diabetologia. 2024;67:1800\u201316.","journal-title":"Diabetologia"},{"key":"1674_CR22","unstructured":"European Medicines Agency. Rybelsus\u00ae Summary of Product Characteristics. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rybelsus-epar-product-information_en.pdf. Accessed 20 June 2024."},{"key":"1674_CR23","unstructured":"U.S. Food and Drug Administration. Rybelsus\u00ae Prescribing Information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/213051s000lbl.pdf. Accessed 20 June 2024."},{"key":"1674_CR24","unstructured":"U.S. Food and Drug Administration. Rybelsus\u00ae Prescribing Information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/213051s018lbl.pdf. Accessed 20 June 2024."},{"key":"1674_CR25","unstructured":"Novo Nordisk. Novo Nordisk announces FDA approval of label update for Rybelsus\u00ae (semaglutide) allowing use as a first-line option for adults with type 2 diabetes [press release]. 2023. https:\/\/www.novonordisk-us.com\/media\/news-archive\/news-details.html?id=154651. Accessed 20 June 2024"},{"issue":"2","key":"1674_CR26","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/17425247.2022.2051476","volume":"19","author":"H Tran","year":"2022","unstructured":"Tran H, ElSayed MEH. Progress and limitations of oral peptide delivery as a potentially transformative therapy. Expert Opin Drug Deliv. 2022;19(2):163\u201378.","journal-title":"Expert Opin Drug Deliv"},{"key":"1674_CR27","unstructured":"ClinicalTrials.gov. A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets (NCT04097600). 2022. https:\/\/clinicaltrials.gov\/study\/NCT04097600. Accessed 20 June 2024."},{"key":"1674_CR28","unstructured":"European Medicines Agency. Guideline on the investigation of bioequivalence (CPMP\/EWP\/QWP\/1401\/98 Rev. 1\/ Corr **). 2010. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 20 June 2024."},{"key":"1674_CR29","unstructured":"U.S. Food and Drug Administration. Bioavailability Studies Submitted in NDAs or INDs\u2014General Considerations Guidance for Industry. 2022. https:\/\/www.fda.gov\/media\/121311\/download. Accessed 20 June 2024."},{"key":"1674_CR30","unstructured":"Pharmaceuticals and Medical Devices Agency and Ministry of Health Labour and Welfare. Guideline for Bioequivalence Studies of Generic Products, PSEHB\/PED Notification No. 0319-1. 2020. https:\/\/www.nihs.go.jp\/drug\/be-guide(e)\/2020\/GL1_BE_2020.pdf. Accessed 20 June 2024."},{"key":"1674_CR31","unstructured":"World Medical Association. WMA declaration of Helsinki\u2014ethical principles for medical research involving human subjects. 2013. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/. Accessed 20 June 2024."},{"key":"1674_CR32","unstructured":"International Council for Harmonisation of technical requirements for pharmaceuticals for human use (ICH). ICH Harmonised Guideline. Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice, E6(R2). 2016. https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf. Accessed 20 June 2024."},{"issue":"10","key":"1674_CR33","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s40262-021-01025-x","volume":"60","author":"RV Overgaard","year":"2021","unstructured":"Overgaard RV, Navarria A, Ingwersen SH, B\u00e6kdal TA, Kildemoes RJ. Clinical pharmacokinetics of oral semaglutide: analyses of data from clinical pharmacology trials. Clin Pharmacokinet. 2021;60(10):1335\u201348.","journal-title":"Clin Pharmacokinet"},{"key":"1674_CR34","unstructured":"U.S. Food and Drug Administration. Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA guidance for industry. 2021. https:\/\/www.fda.gov\/media\/87219\/download. Accessed 20 June 2024."},{"key":"1674_CR35","unstructured":"MedDRA. Introductory Guide for Standardised MedDRA Queries (SMQs) Version 26.0. 2023. https:\/\/admin.meddra.org\/sites\/default\/files\/guidance\/file\/SMQ_intguide_26_0_English.pdf. Accessed 20 June 2024."},{"issue":"8","key":"1674_CR36","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1111\/dom.14054","volume":"22","author":"TK Thethi","year":"2020","unstructured":"Thethi TK, Pratley R, Meier JJ. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme. Diabetes Obes Metab. 2020;22(8):1263\u201377.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1674_CR37","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/dom.12849","volume":"19","author":"ZZ Htike","year":"2017","unstructured":"Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017;19(4):524\u201336.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"1674_CR38","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1007\/s13300-021-01078-y","volume":"12","author":"TA B\u00e6kdal","year":"2021","unstructured":"B\u00e6kdal TA, Breitschaft A, Donsmark M, Maarbjerg SJ, Sondergaard FL, Borregaard J. Effect of various dosing conditions on the pharmacokinetics of oral semaglutide, a human glucagon-like peptide-1 analogue in a tablet formulation. Diabetes Ther. 2021;12(7):1915\u201327.","journal-title":"Diabetes Ther"},{"issue":"8","key":"1674_CR39","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1080\/17425255.2018.1488965","volume":"14","author":"TA B\u00e6kdal","year":"2018","unstructured":"B\u00e6kdal TA, Breitschaft A, Navarria A, Hansen CW. A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide. Expert Opin Drug Metab Toxicol. 2018;14(8):869\u201377.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"1674_CR40","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/jcph.1131","volume":"58","author":"TA B\u00e6kdal","year":"2018","unstructured":"B\u00e6kdal TA, Thomsen M, Kup\u010dov\u00e1 V, Hansen CW, Anderson TW. Pharmacokinetics, safety, and tolerability of oral semaglutide in subjects with hepatic impairment. J Clin Pharmacol. 2018;58(10):1314\u201323.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"1674_CR41","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40262-023-01223-9","volume":"62","author":"M van Hout","year":"2023","unstructured":"van Hout M, Forte P, Jensen TB, Boschini C, B\u00e6kdal TA. Effect of various dosing schedules on the pharmacokinetics of oral semaglutide: a randomised trial in healthy subjects. Clin Pharmacokinet. 2023;62(4):635\u201344.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1674_CR42","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1111\/dom.15493","volume":"26","author":"AB Jain","year":"2024","unstructured":"Jain AB, Reichert SM, Amadid H, et al. Use of once-daily oral semaglutide and associated clinical outcomes among adults with type 2 diabetes in routine clinical practice in Canada: a multicentre, prospective real-world study (PIONEER REAL Canada). Diabetes Obes Metab. 2024;26(5):1799\u2013807.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1674_CR43","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s13300-023-01525-y","volume":"15","author":"A Kick","year":"2024","unstructured":"Kick A, M\u2019Rabet-Bensalah K, Acquistapace F, et al. Real-world use of oral semaglutide in adults with type 2 diabetes: The PIONEER REAL Switzerland multicentre, prospective, observational study. Diabetes Ther. 2024;15(3):623\u201337.","journal-title":"Diabetes Ther"},{"issue":"8","key":"1674_CR44","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1007\/s13300-024-01588-5","volume":"15","author":"W van Houtum","year":"2024","unstructured":"van Houtum W, Schr\u00f6mbges P, Amadid H, et al. Real-world use of oral semaglutide in adults with type 2 diabetes in the PIONEER REAL Netherlands multicentre, prospective, observational study. Diabetes Ther. 2024;15(8):1749\u201368.","journal-title":"Diabetes Ther."},{"key":"1674_CR45","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s13300-024-01614-6","volume":"15","author":"SB Catrina","year":"2024","unstructured":"Catrina SB, Amadid H, Braae UC, et al. PIONEER REAL Sweden: a multicentre, prospective, real-world observational study of oral semaglutide use in adults with type 2 diabetes in Swedish clinical practice. Diabetes Ther. 2024;15:2079\u201395.","journal-title":"Diabetes Ther."},{"key":"1674_CR46","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1111\/jdi.14291","volume":"15","author":"D Yabe","year":"2024","unstructured":"Yabe D, Hamamoto Y, Kawanami D, et al. PIONEER REAL Japan: primary results from a multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice. J Diabetes Investig. 2024;15:1566\u201377.","journal-title":"J Diabetes Investig."},{"issue":"7","key":"1674_CR47","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1111\/dom.15058","volume":"25","author":"DK McGuire","year":"2023","unstructured":"McGuire DK, Busui RP, Deanfield J, et al. Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and\/or chronic kidney disease: design and baseline characteristics of SOUL, a randomized trial. Diabetes Obes Metab. 2023;25(7):1932\u201341.","journal-title":"Diabetes Obes Metab"},{"key":"1674_CR48","unstructured":"Novo Nordisk. Novo Nordisk A\/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial. 2024. https:\/\/www.novonordisk.com\/news-and-media\/news-and-ir-materials\/news-details.html?id=171480. Accessed 01 Nov 2024."}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-024-01674-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-024-01674-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-024-01674-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T04:20:54Z","timestamp":1738642854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-024-01674-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1674"],"URL":"https:\/\/doi.org\/10.1007\/s13300-024-01674-8","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,21]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mette S\u00f8ndergaard Nielsen\u2014Employee and shareholder of Novo Nordisk A\/S. Lise Br\u00f8ndsted\u2014Employee and shareholder of Novo Nordisk A\/S. Martin Kankam\u2014One of the clinical investigators who participated in the conduct of the study, which was sponsored by Novo Nordisk; employee at Altasciences and has received clinical trial funding from Amgen, Biogen, Biohaven, Camino, DynPort, Eli Lilly, EncuraGen, NIH\/DMID, Staidson and Vertex. Gaetano Morelli\u2014Employee at Altasciences. David Nguyen\u2014Employee at Altasciences. Trine Vang Skj\u00f8th\u2014Employee and shareholder of Novo Nordisk A\/S. Usha Rani Patted\u2014Employee of Novo Nordisk India Private Ltd. Marloes van Hout\u2014Employee and shareholder of Novo Nordisk A\/S.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by appropriate health authorities according to local guidelines and by the Institutional Review Board\/Independent Ethics Committee Institutional Review Board, listed in the Supplementary Appendix. The study was conducted in accordance with the Declaration of Helsinki and International Council for Harmonization (ICH) Good Clinical Practice guidelines. Participants provided written informed consent prior to commencement of any study-related activities.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}